{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"3"},{"groupId":"OG001","value":"3"},{"groupId":"OG002","value":"2"},{"groupId":"OG003","value":"20"},{"groupId":"OG004","value":"4"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"3"},{"groupId":"OG001","value":"4"},{"groupId":"OG002","value":"4"},{"groupId":"OG003","value":"36"},{"groupId":"OG004","value":"7"}],"units":"Participants"}],"description":"Response defined as complete response or very good partial response. Complete response defined as the absence of bone marrow or blood findings of multiple myeloma on at least 2 measurements at a minimum of a 6 week interval. Thus all evidence of serum and urinary M-components must disappear on electrophoresis as well as by immunofixation studies. The follow-up bone marrow may not contain more than 5% plasma cells on aspiration or core biopsy and no evidence of increasing anemia. Skeletal X-rays must either show recalcification or no change in osteolytic lesions. Resolution of soft tissue plasmocytomas. Very good partial response defined as reduction of bone marrow or blood findings of multiple myeloma on at least 2 measurements at a minimum of a 6 week interval by greater than or equal to 90%.","groups":[{"description":"See Detailed Description\n\ntotal marrow irradiation: Undergo irradiation escalating according to the following schedule 1000cGy, 1200cGy, 1400cGy, 1600cGy, 1800cGy\n\nmelphalan: Given IV\n\nperipheral blood stem cell transplantation: Undergo transplantation\n\nfilgrastim: Given IV\n\nfluorescence in situ hybridization: Correlative studies\n\ncytogenetic analysis: Correlative studies\n\ncyclophosphamide: Given IV\n\nautologous-autologous tandem hematopoietic stem cell transplantation: Undergo transplantation\n\nlenalidomide: Given orally","id":"OG000","title":"Phase 1 Cohort 1 (Total TMI Dose: 1000 cGy)"},{"description":"See Detailed Description\n\ntotal marrow irradiation: Undergo irradiation escalating according to the following schedule 1000cGy, 1200cGy, 1400cGy, 1600cGy, 1800cGy\n\nmelphalan: Given IV\n\nperipheral blood stem cell transplantation: Undergo transplantation\n\nfilgrastim: Given IV\n\nfluorescence in situ hybridization: Correlative studies\n\ncytogenetic analysis: Correlative studies\n\ncyclophosphamide: Given IV\n\nautologous-autologous tandem hematopoietic stem cell transplantation: Undergo transplantation\n\nlenalidomide: Given orally","id":"OG001","title":"Phase 1 Cohort 2 (Total TMI Dose: 1200 cGy)"},{"description":"See Detailed Description\n\ntotal marrow irradiation: Undergo irradiation escalating according to the following schedule 1000cGy, 1200cGy, 1400cGy, 1600cGy, 1800cGy\n\nmelphalan: Given IV\n\nperipheral blood stem cell transplantation: Undergo transplantation\n\nfilgrastim: Given IV\n\nfluorescence in situ hybridization: Correlative studies\n\ncytogenetic analysis: Correlative studies\n\ncyclophosphamide: Given IV\n\nautologous-autologous tandem hematopoietic stem cell transplantation: Undergo transplantation\n\nlenalidomide: Given orally","id":"OG002","title":"Phase 1 Cohort 3 (Total TMI Dose: 1400 cGy)"},{"description":"See Detailed Description\n\ntotal marrow irradiation: Undergo irradiation escalating according to the following schedule 1000cGy, 1200cGy, 1400cGy, 1600cGy, 1800cGy\n\nmelphalan: Given IV\n\nperipheral blood stem cell transplantation: Undergo transplantation\n\nfilgrastim: Given IV\n\nfluorescence in situ hybridization: Correlative studies\n\ncytogenetic analysis: Correlative studies\n\ncyclophosphamide: Given IV\n\nautologous-autologous tandem hematopoietic stem cell transplantation: Undergo transplantation\n\nlenalidomide: Given orally","id":"OG003","title":"Phase 1 Cohort 4 & Phase 2 MTD (Total TMI Dose:1600 cGy)"},{"description":"See Detailed Description\n\ntotal marrow irradiation: Undergo irradiation escalating according to the following schedule 1000cGy, 1200cGy, 1400cGy, 1600cGy, 1800cGy\n\nmelphalan: Given IV\n\nperipheral blood stem cell transplantation: Undergo transplantation\n\nfilgrastim: Given IV\n\nfluorescence in situ hybridization: Correlative studies\n\ncytogenetic analysis: Correlative studies\n\ncyclophosphamide: Given IV\n\nautologous-autologous tandem hematopoietic stem cell transplantation: Undergo transplantation\n\nlenalidomide: Given orally","id":"OG004","title":"Phase 1 Cohort 5 (Total TMI Dose: 1800 cGy)"}],"paramType":"COUNT_OF_PARTICIPANTS","reportingStatus":"POSTED","timeFrame":"Evaluated after each course until completion of treatment.","title":"Number of Subjects With Response","type":"PRIMARY","unitOfMeasure":"Participants"}